麦科格rab 对两性霉素 B MIC 的非特异性作用。
Nonspecific effect of Mycograb on amphotericin B MIC.
机构信息
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2012 Jul;56(7):3963-4. doi: 10.1128/AAC.00435-12. Epub 2012 Apr 16.
Abstract
Mycograb C28Y is a recombinant human antibody fragment thought to target HSP-90 and potentiate amphotericin B (AMB). Absence of in vivo efficacy led us to reevaluate its in vitro activity. Interactions between AMB and Mycograb were investigated using a checkerboard design. Addition of Mycograb or various unrelated proteins, including human serum, resulted in similar decreases in the MIC of AMB. Potentiation of AMB by Mycograb appears to be a nonspecific protein effect.
摘要
Mycograb C28Y 是一种重组人抗体片段，据认为其可靶向 HSP-90 并增强两性霉素 B（AMB）的活性。体内疗效的缺失促使我们重新评估其体外活性。采用棋盘设计研究了 AMB 与 Mycograb 之间的相互作用。添加 Mycograb 或各种不相关的蛋白质，包括人血清，均可使 AMB 的 MIC 相似降低。Mycograb 增强 AMB 的作用似乎是一种非特异性蛋白效应。
相似文献
1
Nonspecific effect of Mycograb on amphotericin B MIC.麦科格rab 对两性霉素 B MIC 的非特异性作用。
Antimicrob Agents Chemother. 2012 Jul;56(7):3963-4. doi: 10.1128/AAC.00435-12. Epub 2012 Apr 16.
2
Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.采用棋盘法和时间杀菌法评估米卡芬净、两性霉素B、卡泊芬净和氟康唑联合抗新生隐球菌的效果。
Diagn Microbiol Infect Dis. 2005 Jan;51(1):19-29. doi: 10.1016/j.diagmicrobio.2004.08.013.
3
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.C28Y 变体的 Mycograb 剂量范围评估，C28Y 变体是人源重组热休克蛋白 90 抗体片段，与两性霉素 B-去氧胆酸盐联合用于治疗小鼠系统性念珠菌病。
Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.
4
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.氟康唑、两性霉素 B 和卡泊芬净对流动条件下白色念珠菌生物膜的影响及其对生物膜分散的作用。
Antimicrob Agents Chemother. 2011 Jul;55(7):3591-3. doi: 10.1128/AAC.01701-10. Epub 2011 Apr 25.
5
In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms.高剂量强力霉素与抗真菌剂联合对抗白色念珠菌生物膜的体外分析
Int J Antimicrob Agents. 2009 Oct;34(4):326-32. doi: 10.1016/j.ijantimicag.2009.04.011. Epub 2009 Jun 9.
6
Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.白色念珠菌中对卡泊芬净敏感性降低的突变体的产生：对其他抗真菌药物的影响。
J Chemother. 2010 Aug;22(4):283-4. doi: 10.1179/joc.2010.22.4.283.
7
Antifungal combinations against Candida albicans biofilms in vitro.体外抗白色念珠菌生物膜的抗真菌联合用药
Antimicrob Agents Chemother. 2003 Nov;47(11):3657-9. doi: 10.1128/AAC.47.11.3657-3659.2003.
8
In vitro activity of antifungal combinations against Candida albicans biofilms.抗真菌药物联合应用对白色念珠菌生物膜的体外活性研究
J Antimicrob Chemother. 2010 Feb;65(2):271-4. doi: 10.1093/jac/dkp429. Epub 2009 Dec 8.
9
10
Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases.两性霉素 B、卡泊芬净和泊沙康唑对处于中、成熟期的白色念珠菌生物膜的抗真菌活性。
Mycoses. 2010 May;53(3):208-14. doi: 10.1111/j.1439-0507.2009.01690.x. Epub 2009 Feb 26.
引用本文的文献
1
Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.利用免疫应答开发针对真菌病原体的疫苗
Annu Rev Microbiol. 2022 Sep 8;76:703-726. doi: 10.1146/annurev-micro-041020-111511. Epub 2022 Jun 27.
2
The role of stress response pathways in antifungal tolerance and resistance.应激反应途径在抗真菌耐受性和抗性中的作用。
iScience. 2022 Feb 19;25(3):103953. doi: 10.1016/j.isci.2022.103953. eCollection 2022 Mar 18.
3
The Role of B-Cells and Antibodies against Vaccine Antigens in Invasive Candidiasis.B细胞和抗疫苗抗原抗体在侵袭性念珠菌病中的作用
Vaccines (Basel). 2021 Oct 10;9(10):1159. doi: 10.3390/vaccines9101159.
4
Biological and Physico-Chemical Characteristics of Arginine-Rich Peptide Gemini Surfactants with Lysine and Cystine Spacers.富含精氨酸的肽型双子表面活性剂的赖氨酸和胱氨酸间隔基的生物和物理化学特性。
Int J Mol Sci. 2021 Mar 24;22(7):3299. doi: 10.3390/ijms22073299.
5
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.先天灵感：宿主免疫反应中的抗真菌肽和其他免疫疗法。
Front Immunol. 2020 Sep 17;11:2177. doi: 10.3389/fimmu.2020.02177. eCollection 2020.
6
Targeting Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model.在中性粒细胞减少的大鼠模型中，用中和抗体靶向Crf转糖基酶虽有相关性，但不足以消除真菌负荷。
Front Microbiol. 2019 Mar 26;10:600. doi: 10.3389/fmicb.2019.00600. eCollection 2019.
7
Immunomodulation as Therapy for Fungal Infection: Are We Closer?免疫调节作为真菌感染的治疗方法：我们更接近目标了吗？
Front Microbiol. 2018 Jul 25;9:1612. doi: 10.3389/fmicb.2018.01612. eCollection 2018.
8
The Elusive Anti- Vaccine: Lessons From the Past and Opportunities for the Future.难以捉摸的反疫苗：从过去吸取的教训和未来的机会。
Front Immunol. 2018 Apr 27;9:897. doi: 10.3389/fimmu.2018.00897. eCollection 2018.
9
Heat Shock Proteins and Hsps-Associated Signaling Pathways as Potential Antifungal Targets.热休克蛋白及与 Hsps 相关的信号通路作为潜在的抗真菌靶点。
Front Cell Infect Microbiol. 2017 Dec 19;7:520. doi: 10.3389/fcimb.2017.00520. eCollection 2017.
10
Antimicrobial Activity and Resistance: Influencing Factors.抗菌活性与耐药性：影响因素
Front Pharmacol. 2017 Jun 13;8:364. doi: 10.3389/fphar.2017.00364. eCollection 2017.
本文引用的文献
1
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.C28Y 变体的 Mycograb 剂量范围评估，C28Y 变体是人源重组热休克蛋白 90 抗体片段，与两性霉素 B-去氧胆酸盐联合用于治疗小鼠系统性念珠菌病。
Antimicrob Agents Chemother. 2011 Jul;55(7):3295-304. doi: 10.1128/AAC.01324-10. Epub 2011 Apr 18.
2
Monoclonal antibody-based therapies for microbial diseases.基于单克隆抗体的微生物疾病治疗方法。
Vaccine. 2009 Dec 30;27 Suppl 6:G38-46. doi: 10.1016/j.vaccine.2009.09.105.
3
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.一项针对侵袭性念珠菌病患者的随机、双盲、多中心试验，比较单独使用脂质体两性霉素B与联合使用基于抗体的热休克蛋白90抑制剂的效果。
Clin Infect Dis. 2006 May 15;42(10):1404-13. doi: 10.1086/503428. Epub 2006 Apr 12.
4
Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.采用棋盘法和时间杀菌法评估米卡芬净、两性霉素B、卡泊芬净和氟康唑联合抗新生隐球菌的效果。
Diagn Microbiol Infect Dis. 2005 Jan;51(1):19-29. doi: 10.1016/j.diagmicrobio.2004.08.013.
5
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.抗真菌热休克蛋白90人重组抗体Mycograb疗效的临床前评估。
Antimicrob Agents Chemother. 2003 Jul;47(7):2208-16. doi: 10.1128/AAC.47.7.2208-2216.2003.
6
Influence of human serum on antifungal pharmacodynamics with Candida albicans.人血清对白色念珠菌抗真菌药效学的影响。
Antimicrob Agents Chemother. 2001 Jul;45(7):2018-22. doi: 10.1128/AAC.45.7.2018-2022.2001.
7
Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages.铁在人血清或单核细胞衍生巨噬细胞存在的情况下对氟康唑抗白色念珠菌活性的影响。
Mycopathologia. 1997;138(1):29-35. doi: 10.1023/a:1006889108673.
8
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.两性霉素B和氟康唑对白色念珠菌细胞外和细胞内生长的影响。
Antimicrob Agents Chemother. 1991 Nov;35(11):2275-81. doi: 10.1128/AAC.35.11.2275.
Zotero 插件